indication directory

Multiple Myeloma clinical trial intelligence

Trials are included only when the source condition or controlled indication mapping directly matches this disease area. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

indication

Association rule

source condition

NCT03839459

Source recordAI-normalized

Denosumab for Smoldering Multiple Myeloma

This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.

AI analysis

Indication: Smoldering Multiple Myeloma

Modality: monoclonal antibody

Target: Denosumab

Sponsor: University of Rochester

Source URL: ClinicalTrials.gov

Source updated: Jan 28, 2026

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Smoldering Multiple Myeloma

View original source fields

Condition raw: Smoldering Multiple Myeloma

Condition normalized: Smoldering Multiple Myeloma

Modality raw: monoclonal antibody

Modality normalized: monoclonal antibody

Target raw: Denosumab

Target normalized: Denosumab

Open report

NCT00104650

Source recordAI-normalized

A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates

The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.

AI analysis

Indication: Bone Metastases in Men With Hormone-Refractory Prostate Cancer

Modality: gene therapy

Target: AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks

Sponsor: Amgen

Source URL: ClinicalTrials.gov

Source updated: Jan 24, 2011

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

View original source fields

Condition raw: Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

Condition normalized: Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

Modality raw: gene therapy

Modality normalized: gene therapy

Target raw: AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks

Target normalized: AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks

Open report

NCT03224507

Source recordAI-normalized

Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma - MASTER Trial

Multiple myeloma (MM), a plasma cell disorder, is the second most common hematologic malignancy in the U.S. No standard curative therapy has yet been found. A variety of therapeutic measures including high dose melphalan, induction therapy, and continuous therapy have been used but the goal of complete response without relapse has not been achieved. More active treatment regimens and better tools for response assessment are needed.

AI analysis

Indication: Multiple Myeloma

Modality: small molecule

Target: KRdD followed by auto-HCT, KRdD only

Sponsor: University of Alabama at Birmingham

Source URL: ClinicalTrials.gov

Source updated: Nov 24, 2023

Ingested: Jun 09, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Multiple Myeloma

View original source fields

Condition raw: Multiple Myeloma

Condition normalized: Multiple Myeloma

Modality raw: small molecule

Modality normalized: small molecule

Target raw: KRdD followed by auto-HCT, KRdD only

Target normalized: KRdD followed by auto-HCT, KRdD only

Open report

NCT00991562

Source recordAI-normalized

An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma

The purpose of this study is to test IMGN901 in combination with lenalidomide and dexamethasone every 28 days.

AI analysis

Indication: Multiple Myeloma

Modality: small molecule

Target: IMGN901

Sponsor: ImmunoGen, Inc.

Source URL: ClinicalTrials.gov

Source updated: Nov 21, 2014

Ingested: May 23, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Multiple Myeloma

View original source fields

Condition raw: Multiple Myeloma

Condition normalized: Multiple Myeloma

Modality raw: Multiple Myeloma

Modality normalized: small molecule

Target raw: IMGN901

Target normalized: IMGN901

Open report